10:15 AM EDT, 07/08/2024 (MT Newswires) -- Immix Biopharma ( IMMX ) said Monday the first patient has been dosed in a US trial of AL amyloidosis with NXC-201.
The trial is assessing the safety and efficacy of the candidate drug in people with relapsed/refractory AL amyloidosis, the company said, adding the trial builds on "positive" data from an initial ex-US trial.
Price: 2.30, Change: -0.06, Percent Change: -2.50